Equity securities

Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock

Retrieved on: 
Monday, August 2, 2021
Finance, Financial markets, Financial economics, Stock market, Corporate finance, Financial District, San Francisco, Equity securities, Initial public offering, SVB Leerink, Evercore, Stock, Wells Fargo

In addition, Avidity intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.

Key Points: 
  • In addition, Avidity intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
  • All of the shares to be sold in the offering are to be sold by Avidity.
  • There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Cowen, SVB Leerink, Evercore ISI and Wells Fargo Securities are acting as joint bookrunning managers for the offering.

MISONIX ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MSON and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, July 30, 2021
Corporate finance, Financial economics, Finance, Stock market, Money, Equity securities, Security, Stock, Common stock, Derivative, United States corporate law, Mergers and acquisitions

On July 29, 2021, Misonix announced that it had entered into an agreement to merge with Bioventus in a deal valued at approximately $518 million.

Key Points: 
  • On July 29, 2021, Misonix announced that it had entered into an agreement to merge with Bioventus in a deal valued at approximately $518 million.
  • Pursuant to the merger agreement, Misonix stockholders will have the choice to receive either $28 in cash or 1.6839 shares of Bioventus common stock for each share of Misonix common stock owned.
  • Bragar Eagel & Squire is concerned that Misonixs board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Transaction in own shares

Retrieved on: 
Friday, July 30, 2021
Equity securities, Corporate finance, Financial economics, Common stock, Finance, Money

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Arix intends to retain the purchased shares in treasury.
  • Following settlement of the above purchase, Arix will have 130,880,800 ordinary shares of 0.001 pence each in issue (excluding 4,728,853 ordinary shares of 0.001p each held in treasury).
  • In accordance with Article 5(1)(b) of Regulation (EU) No.

Transaction in own shares

Retrieved on: 
Friday, July 30, 2021
Equity securities, Corporate finance, Financial economics, Common stock, Finance, Money

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Arix intends to retain the purchased shares in treasury.
  • Following settlement of the above purchase, Arix will have 130,898,800 ordinary shares of 0.001 pence each in issue (excluding 4,710,853 ordinary shares of 0.001p each held in treasury).
  • In accordance with Article 5(1)(b) of Regulation (EU) No.

Halfords Group PLC: Total Voting Rights

Retrieved on: 
Friday, July 30, 2021
Financial markets, Corporate finance, Equity securities, Financial economics, Finance, Halfords, Public limited company, Common stock, Stock market

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • As at the date of this announcement, the registered share capital of Halfords Group plc (the "Company") consists of 199,116,632 ordinary shares of 1p each.
  • All of the ordinary shares have equal voting rights and there are no shares held in Treasury.
  • This disclosure is given in accordance with DTR 5.6.1 of the Disclosure Guidance and Transparency Rules.

XBiotech Announces Payment of Dividend to Holders of Common Stock

Retrieved on: 
Friday, July 30, 2021
Financial markets, Corporate finance, Financial economics, Equity securities, Stock market, Dividends, Shareholders, Ex-dividend date, Common stock, Stock, Share

AUSTIN, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (XBiotech) has completed payment to holders of its Common Stock of a previously announced dividend in the amount of USD$75,000,000.00.

Key Points: 
  • AUSTIN, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (XBiotech) has completed payment to holders of its Common Stock of a previously announced dividend in the amount of USD$75,000,000.00.
  • Based on the number of shares of Common Stock issued and outstanding on the record date for the dividend, each such holder received USD$2.47 per share on July 23, 2021.
  • John Simard stated that XBiotech was pleased to be able to reward its shareholders with a $2.47 per share dividend.
  • Our ability to continue to provide opportunities for shareholders to monetize stock in XBiotech, reflects the strength of our fundamental approach to our industry.

TELUS Corporation Notice of Cash Dividend

Retrieved on: 
Friday, July 30, 2021
Financial markets, Finance, Corporate finance, Equity securities, Stock market, Shareholders, Share, Common stock, Dividends, Ex-dividend date

VANCOUVER, British Columbia, July 30, 2021 (GLOBE NEWSWIRE) -- NOTICE IS HEREBY GIVEN that the Board of Directors has declared a quarterly dividend of $0.3162 Canadian per share on the issued and outstanding Common shares payable on October 1, 2021 to shareholders of record at the close of business on September 10, 2021.

Key Points: 
  • VANCOUVER, British Columbia, July 30, 2021 (GLOBE NEWSWIRE) -- NOTICE IS HEREBY GIVEN that the Board of Directors has declared a quarterly dividend of $0.3162 Canadian per share on the issued and outstanding Common shares payable on October 1, 2021 to shareholders of record at the close of business on September 10, 2021.

Cerevel Therapeutics Announces Redemption of Public Warrants

Retrieved on: 
Friday, July 30, 2021
Finance, Money, Equity securities, Options, Financial markets, Corporate finance, Warrant, NASDAQ

ET on August 30, 2021 will be void and no longer exercisable, and the holders of those public warrants will be entitled to receive only the redemption price of $0.01 per warrant.

Key Points: 
  • ET on August 30, 2021 will be void and no longer exercisable, and the holders of those public warrants will be entitled to receive only the redemption price of $0.01 per warrant.
  • As a result of the redemption, the public warrants will cease to be traded on Nasdaq following the close of trading on August 30, 2021.
  • Beneficial holders seeking to exercise public warrants should contact their brokerage firm as soon as possible to process the warrant exercise in advance of the redemption date.
  • Brokers may have an earlier deadline for beneficial holders to exercise their public warrants than the deadline set forth above.

Matthews International Corporation Announces Continuation of Its Stock Repurchase Program

Retrieved on: 
Friday, July 30, 2021
Stock market, Financial economics, Finance, Corporate finance, Money, Share repurchase, Equity securities, Dividend, Stock, Repurchase agreement

PITTSBURGH, July 30, 2021 (GLOBE NEWSWIRE) -- Matthews International Corporation (NASDAQ GSM: MATW) today announced that its Board of Directors approved a continuation of the Companys stock repurchase program.

Key Points: 
  • PITTSBURGH, July 30, 2021 (GLOBE NEWSWIRE) -- Matthews International Corporation (NASDAQ GSM: MATW) today announced that its Board of Directors approved a continuation of the Companys stock repurchase program.
  • Upon the repurchase of these remaining shares, the new authorization allows Matthews to purchase up to an additional 2,500,000 shares of the Companys common stock.
  • In addition to our quarterly cash dividends, we continue to believe that the repurchase program is an effective means to return capital to our shareholders.
  • Matthews International Corporation is a global provider of brand solutions, memorialization products and industrial technologies.

Electrum Strategic Opportunities Fund II L.P. Sells Common Shares of Constantine Metal Resources Ltd.

Retrieved on: 
Thursday, July 29, 2021
Financial markets, Financial economics, Finance, Equity securities, Stock market, Corporate finance, Options, Warrant, Security, Convertible security, Electrum, Share

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) --  Electrum Strategic Opportunities Fund II L.P. (“Electrum”) has sold, pursuant to the terms of certain share purchase agreements dated July 29, 2021 (the “Purchase Agreements”), 4,411,764 common shares (the “Purchased Shares”) of Constantine Metal Resources Ltd. (the “issuer”) to certain third-party purchasers (the “Transaction”) for $0.27 per Purchased Share for a total purchase price of $1,191,176.28 (the “Purchase Price”).

Key Points: 
  • NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Electrum Strategic Opportunities Fund II L.P. (Electrum) has sold, pursuant to the terms of certain share purchase agreements dated July 29, 2021 (the Purchase Agreements), 4,411,764 common shares (the Purchased Shares) of Constantine Metal Resources Ltd. (the issuer) to certain third-party purchasers (the Transaction) for $0.27 per Purchased Share for a total purchase price of $1,191,176.28 (the Purchase Price).
  • As a result of the Transaction, Electrum currently owns no common shares and 8,823,529 warrants (Warrants) representing 15.3% of the issued and outstanding common shares (Common Shares) upon the exercise of the Warrants (assuming that all of the Warrants owned by Electrum immediately following the Closing are exercised and that no other securities, including those convertible into, or exercisable for, Common Shares, are issued, converted or exercised).
  • Electrum Global Holdings L.P., a joint actor (as such term is defined in National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues) of Electrum, owns 250,000 Common Shares representing 0.51% of the Common Shares of the issuer.
  • Electrum is located at 535 Madison Avenue, 12th Floor, New York, NY 10022, USA.